Vendors to Watch for Real-World Evidence, Data, Platforms, Technologies, and Consulting Services

This IDC Perspective reviews vendors to watch in the real-world evidence (RWE), data, platforms, technologies, and consulting and provides guidance to technology buyers."As the importance of RWD/RWE continues to grow exponentially, the life sciences industry is exploring a rapidly evolving landscape of well-established large players and a boiling cauldron of innovative start-ups. Vendors are also pulling out all the stops to ensure that they innovate and differentiate. Pharmas and biotechs are reevaluating legacy partnerships, looking at long-term strategic alignment, and recognizing that these are not easy decisions. Multiple criteria need to be examined, and the fact that these decisions can have a direct impact on regulatory approvals, costs, and time to market needs to be factored in when architecting a RWD/RWE strategy," said Dr. Nimita Limaye, research VP, Life Sciences R&D Strategy and Technology, IDC.